New Pathways for Treating Metastatic Castration-Resistant Prostate Cancer (mCRPC) VL

AKT Inhibitors – Targeting PI3K/AKT/MTOR Signaling Axis - Cora Sternberg

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Cora N. Sternberg, MD, FACP, Clinical Director of the Englander Institute for Precision Medicine, Professor of Medicine, Weill Cornell Medicine, Meyer Cancer Center New York, Presbyterian, NY Alicia Morgans, MD, MPH , Geni...

Real World Evidence Evaluating the Underutilization of Treatments for mCRPC in Clinical Practice - Mark Fleming

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC. Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Mark Fleming, MD, GU Disease Committee Chair, Sarah Connon Research Institute, President, Virginia Oncology Association, Norfolk, VA Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Atlantic U...

Broadening Treatment Horizons with CDK4/6 Inhibitors from Breast to Prostate Cancer - Rana McKay

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Rana R. McKay, Medical Oncologist, Associate Professor, University of California, San Diego, San Diego, CA Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber...

Bone Health Management for Advanced Prostate Cancer - Fred Saad

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC. Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Fred Saad, MD, FRSC, Professor, Department of Surgery, Raymond Garneau Chair in Prostate Cancer, Université de Montréal, Montréal, QC Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Atlantic...

Tumor Heterogeneity Selective Pressure – Why We Need New Targets? - Oliver Sartor

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: A. Oliver Sartor, MD, Disease Group Leader GU Cancers, Director of Radiopharmaceutical Trials, Mayo Clinic, Rochester, MN Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program...

Unlocking Precision Care: Germline & Somatic Literacy in Prostate Cancer - Elisabeth Heath

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC. Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Elisabeth I. Heath, MD, FACP, Associate Center Director of Translational Sciences, Hartmann Endowed Chair for Prostate Cancer Research Chair, Genitourinary Multidisciplinary Team, Professor of Oncology and Medicine, Karma...

Unlocking the Future of mCRPC Treatment: Exploring Immune Checkpoint Inhibitors for MMR Loss and MSI-High - Sumit Subudhi

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Sumit K. Subudhi, Associate Professor, Department of Genitourinary Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center,...

PARP Inhibitors: Targeting DNA Repair Pathways - Neal Shore

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC. Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Neal Shore, MD, FACS, Director, CPI (Certified Principal Investigator by the Association of Clinical Research Professionals), Medical Director for the Carolina Urologic Research Center and practices with Atlantic Urology...

The Biological Basis of Metastatic Prostate Cancer – The Unmet Medical Need for New Targets and Novel Treatment Pathways - Dan George

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Daniel George, MD, Medical Oncologist, Professor, Departments of Medicine and Surgery, Leader, DCI Center for Prostate and Urologic Cancers, Duke Cancer Institute, Duke University, Durham, NC Alicia Morgans, MD, MPH , Geni...

The Critical Intersection of Androgen Receptor Pathways and Cell Cycle Regulation in Prostate Cancer Therapy - Rana McKay

Details
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC. Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Rana R. McKay, Medical Oncologist, Associate Professor, University of California, San Diego, San Diego, CA Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farbe...